Scinai Immunotherapeutics Ltd. (SCNI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Jerusalem BioPark Building
Jerusalem, JM 9112001
Israel
Phone
972 8 930 2529
Website
Sector
Healthcare
Industry
Biotechnology
Employees
45
First IPO Date
May 11, 2015
| Name | Title | Pay | Year Born |
| Amir Reichman | Chief Executive Officer & Director | 391,000 | 1976 |
| Uri Ben-Or | Chief Financial Officer | 175,000 | 1970 |
| Elad Mark | Chief Operating Officer | 239,000 | 1983 |
| Eran Kuratz | Head of Supply Chain & Business Process Administration | 0 | N/A |
| Naama Adi Hen | Head of Quality Asurance | 0 | N/A |
| Gal Ron | Head of HR | 0 | N/A |
| Merav Kamensky | Head of Quality Control & GMP Analytics | 0 | N/A |
| Tehila Sonnenfeld | Head of Manufacturing | 0 | N/A |
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.